Literature DB >> 26956094

Higher risk of urothelial carcinoma in the upper urinary tract than in the urinary bladder in hemodialysis patients.

Po-Jen Hsiao1, Po-Fan Hsieh1, Chao-Hsiang Chang1, Hsi-Chin Wu1,2, Chi-Rei Yang1, Chi-Ping Huang1,3.   

Abstract

Purpose This study used the a nationwide population-based retrospective cohort study with the claims data from the Taiwan National Health Insurance Research Database to investigate the risk of urothelial carcinoma (UC) for hemodialysis (HD) patients. Methods The study population consisted of 2689 patients with end-stage renal disease (ESRD) newly diagnosed in 2000-2002 and underwent maintenance HD. Then, 21,449 reference patients were collected without HD randomly selected and matched with sex and age. The exclusion criteria were previous long-term analgesics and Chinese medication usage. Incidence density rates of UC in upper urinary tract (UTUC) and bladder (UBUC) were estimated for both cohorts by the end of 2012. Hazard ratios (HRs) of UC were measured in association with HD, covariates, and comorbidity. Results The incidence of UC was significantly higher in the HD cohort than in the reference cohort for both UT (21.8 vs. 0.65 per 10,000 person-years) and UB (17.7 vs. 3.55 per 10,000 person-years). The multivariate Cox proportional hazard regression analysis showed that the HRs of UTUC in HD cohort was 33.3 (95% CI = 15.9-69.5) and 5.14 for UBUC (95% CI = 3.24-8.15). The risk increased further for HD patients with comorbidity of hematuria, urinary tract infection (UTI) or hydronephrosis. Conclusion Patients with ESRD on HD are at a high risk of developing UC, especially UTUC in Taiwan. They will be paid more frequent to check urine analysis, urine cytology, and upper urinary tract survey.

Entities:  

Keywords:  End-stage renal disease; hemodialysis; upper urinary tract; urinary bladder; urothelial carcinoma,

Mesh:

Year:  2016        PMID: 26956094     DOI: 10.3109/0886022X.2016.1155392

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  2 in total

1.  The incidence and prevalence of upper tract urothelial carcinoma: a systematic review.

Authors:  Ahmed Soualhi; Elke Rammant; Gincy George; Beth Russell; Deborah Enting; Rajesh Nair; Mieke Van Hemelrijck; Cecilia Bosco
Journal:  BMC Urol       Date:  2021-08-17       Impact factor: 2.264

2.  Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.

Authors:  Huan Lu; Yuan Liang; Bao Guan; Yue Shi; Yanqing Gong; Juan Li; Wenwen Kong; Jin Liu; Dong Fang; Libo Liu; Qun He; Muhammad Shakeel; Xuesong Li; Liqun Zhou; Weimin Ci
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.